InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

VANCOUVER, May 11, 2018

"During the third quarter of fiscal 2018, InMed continued to execute on its R&D and business strategy," stated President and Chief Executive Officer, Eric A. Adams.  "InMed is making headway at establishing its leadership position as a fully-integrated cannabinoid pharmaceutical company; we are not only developing innovative therapies for the treatment of important diseases with high unmet medical needs, but are also leading the burgeoning cannabinoid sector with our first-in-class biosynthetic manufacturing technology.  "Over the next several months," Mr. Adams concluded, "we will remain focused on building shareholder value via innovative scientific research and development, as well as attaining greater exposure within the investment community in the United States."

Business and R&D Update:

• Biosynthesis manufacturing technology. The Company, in conjunction with its collaborators at the University of British Columbia, continued to advance the production platform for the bio-fermentation of cannabinoids. Optimization of the vector will continue in parallel with the identification of optimal fermentation conditions and downstream purification processes with yet-to-be announced 3^rd party suppliers, who are currently being vetted.
  
  
• INM-750 for the treatment of the rare disease epidermolysis bullosa (EB). During the three months ended March 31, 2018, the Company continued working to finalize the formulation for INM-750 and initiated work on IND-enabling pharmacology and toxicology studies. The Company currently anticipates that it will be discussing its clinical development plans with regulatory authorities in the second half of 2018. After further data analysis in preparation for these discussions, InMed has determined that additional pre-clinical pharmacology experiments are warranted. We now expect to file our Investigational New Drug ("IND") application in the second half of calendar-year 2019. These experiments will be designed to ensure that INM-750 meets the clinical needs of EB patients and improve the overall prospects of success for the INM-750 development program. In particular, these experiments will help us better understand the contributions of each cannabinoid component as well as their final combination in INM-750. Specifically, these additional pre-clinical experiments will focus on the effects these compounds have on wound healing and the reduction of inflammation.
  
  
• INM-085 for the treatment of glaucoma. InMed announced the publication of a peer-reviewed article in Drug Delivery and Translational Research on March 6, 2018. The article, titled "A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery", presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed's Chief Scientific Officer. Data from this study support what the Company believes to be a first-in-class nanoparticle-hydrogel formulation for cannabinoid delivery to the eye, resulting in significant delivery of cannabinoids to the eye via transcorneal penetration, resulting in a 300% increase versus a control formulation. Next steps in this program will include additional preclinical efficacy testing and advanced formulation development.
   
  
• On March 13, 2018, InMed announced the appointment of Eric Hsu, Ph.D., as Vice President of Preclinical Research and Development.

Corporate Update (expressed in Canadian Dollars):

• During the quarter ending March 31, 2018, the Company issued an aggregate 25,143,531 common shares, pursuant to InMed's $9.4 million private placement (13,428,571 shares issued) completed on January 3, 2018, as well as the exercise of investor and agents' warrants (5,648,947 shares issued), and stock options (6,030,295 shares issued) and as consideration for services provided (35,718 shares). At March 31, 2018, the Company's total issued and outstanding shares were 152,792,997. During 3Q18, the weighted average number of common shares was 151,537,571, which is used for the calculation of loss per share.
  
  
• Effective March 26, 2018, the Company commenced trading on the Toronto Stock Exchange.

Results of Operations (expressed in Canadian Dollars):

• For the three and nine months ended March 31, 2018, the Company recorded a net loss of $2.13 million and $5.49 million or $0.01 and $0.04 per share, respectively, compared with a net loss of $1.24 million and $2.6 million, or $0.01 and $0.03 per share, for the three and nine months ended March 31, 2017.
  
  
• Research and development expenses were $0.55 million for the three months ended March 31, 2018, compared with $0.17 million for the three months ended March 31, 2017. For the nine months ended March 31, 2018, research and development expenses totaled $1.35 million, which compares with $0.37 million for the corresponding period in 2017. The increase in research and development expenses in the three months ended March 31, 2018 as compared to the same quarter in 2017 was primarily due to increased spending with external contractors for expenditures related to the advancement of INM-750 as a treatment for EB.
  
  
• The Company incurred general and administrative expenses of $0.81 million for the three months ended March 31, 2018, compared with $0.88 million for the three months ended March 31, 2017. For the nine months ended March 31, 2018, general and administrative expenses totaled $2.39 million, which compares with $1.57 million for the corresponding period in 2017.
  
  
• The Company also incurred non-cash, share-based payments, in connection with the grant of stock options, of $0.76 million for the three months ended March 31, 2018, compared with $0.15 million for the three months ended March 31, 2017. For the nine months ended March 31, 2018, non-cash, share-based payments totaled $1.69 million, which compares with $0.59 million for the corresponding period in 2017.
  
  
• At March 31, 2018, the Company's cash, cash equivalents and short-term investments were $13.88 million, which compares to $6.71 million at June 30, 2017. During the nine months to March 31, 2018, the Company's cash, cash equivalents and short-term investments increased by $7.17 million, which primarily resulted from net cash proceeds of $8.63 million from with its non-brokered private placement completed on January 3, 2018 and $1.90 million proceeds from the exercise of warrants and stock options less $3.30 million cash outflows from operating activities.

Table 1:  Condensed consolidated interim statements of financial position (un-audited):